ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday

ARS Pharmaceuticals (NASDAQ:SPRY) is projected to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $25.5840 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

ARS Pharmaceuticals Stock Down 3.3%

SPRY opened at $8.87 on Wednesday. ARS Pharmaceuticals has a 1-year low of $6.66 and a 1-year high of $18.90. The stock’s fifty day simple moving average is $10.33 and its 200 day simple moving average is $10.21. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. The stock has a market cap of $876.80 million, a PE ratio of -10.95 and a beta of 0.78.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creek Drive Management Group LLC acquired a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $3,447,000. FAS Wealth Partners Inc. lifted its position in shares of ARS Pharmaceuticals by 0.9% during the 4th quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock valued at $2,358,000 after acquiring an additional 1,787 shares during the period. VARCOV Co. acquired a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth $260,000. Osterweis Capital Management Inc. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth $65,000. Finally, Millennium Management LLC acquired a new position in ARS Pharmaceuticals in the fourth quarter valued at about $36,912,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SPRY. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Zacks Research raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Roth Mkm assumed coverage on ARS Pharmaceuticals in a report on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ARS Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $30.67.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.